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Remembering the past is useful to gain perspective on the future. Unna, the great dermatopathologist, in 1896 described hair suddenly breaking off at the surface with the characteristic point of a� exclama­tion. He noted that the course was chromc and that 
long remissions, rapid relapses, and improvements were parts of the 
course. He also suggested "the microorganism of this disease is still 
unknown although the disease is certainly contagious." Although 
no one thinks the disease is contagious, in the usual sense, with 
techniques of polymerase chain reaction (PCR) there is and will be 
concerns about potential organisms. Looking back at the workshop 
in toto and comparing it with the first workshop, there has been a 
marked number of advances including more details on the under­
standing of the animal models, defining of the HLA linkages on a 
precise molecular basis, more creditable description of the autoan­
tibodies and antigens, and the role of lymphokines. Particularly 
encouraging is the new technology that is applicable to the hair 
follicle. As a primary target, the dermal papilla, from the studies of 
several of the presenters, looks like a major focus for disease. 
Investigations on the biology of that structure will certainly be 
important. 
Some of the new technologies described at this meeting will be 
extremely useful in the future, including such technologies as single 
hair follicular culture, single hair reverse transcriptase-PCR (RT­
PCR) , follicular reconstitution, and elegant nude mouse grafting 
studies. Although there have been significant advances in basic 
biology of the hair follicle there have been much slower advances 
in terms of new therapeutic modalities. The description of the 
immune mediators in the process, however, gives hope that new 
immune-based therapies will be possible. 
The animal models for alopecia areata are extremely interesting 
and will have several uses. Those uses include identification of the 
molecular basis of the disease and elucidation of basic pathophysi­
ologies-although it is recognized that there may be some differ­
ences between the rodent model and the human disease. If there are 
similarities in the immune mechanisms in the animal models of 
alopecia areata, those models will be extremely important for 
testing the validity of novel immunologic therapies. 
In terms of what is needed for future research, elucidating 
triggering events such as potential viral diseases are extremely 
important. The field of psychoneuroimmL . alogy may clarifY the 
relationship of stress and hair loss. Remissions of alopecia areata 
suggest that studies emphasizing down-regulation of the immune 
response will also be important. It seems remarkable that human 
immunodeficiency virus infection neither worsens nor improves 
alopecia areata. There have been case reports of individuals with 
HIV and alopecia areata, and a systematic study of the association of 
these two diseases may be of interest. 
There is need for a more precise and uniform international 
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clinical classification of alopecia areata to be used by all investiga­
tors. It is recommended that the various national and international 
organizations working on hair research develop such a classification 
and all investigators use that classification. As the molecular 
immunologic studies are done it is vital that patients in the studies 
are in the same clinical categories. Another question of great 
interest is whether the age of onset will be a surrogate for the 
familial forms of alopecia areata and for longstanding alopecia 
totalis (AT) and alopecia universalis (AU). Data was presented that 
37% of patients with onset by age 30 had a positive family history 
for alopecia areata whereas only 7% of patients with onset after age 
30 had a positive family history. Additional findings were reported 
that 45% of patients with long-standing AT! AU developed their 
first patch by age 10 years, whereas only 10% of patients with 
long-standing patchy alopecia areata (who never had AT! AU) 
developed their first patch by age 10 years. At the same time, the 
majority of patients with long-standing disease, both long-standing 
patchy alopecia areata and longstanding AT! AU, developed their 
first patch of alopecia areata by age 40 years. These are important 
findings that should be amplified in future studies. 
New paradigms for alopecia areata were presented. There was 
good evidence that some of the complexities in analyzing alopecia 
areata are related to there being two sets of genetics factors: one 
determining the susceptibility to the disease and one the severity of 
the disease. There may be both immune and non-immune features 
of both susceptibility and severity. Realizing that there are at least 
two possibly independent genetic factors is important for analyzing 
the data. 
Work by several presenters also suggested that hair in "normal" 
or "unaffected" areas of the scalp is abnormal and shows the 
inflarmnatory changes. This is another important point to confirm 
and quantitate. The dermal papilla is a site that deserves in-depth 
studies, especially regarding changes in the normal hair cycle. In 
addition to the fibroblast-like cell that can be cultured and that has 
many of the biologic effects of the dermal papilla there are several 
other cell types that should have their cellular and molecular 
biology determined. Elegant autoexperiments were described in 
which terminal hair could be grown on general body epidermis 
from the isolated dermal papilla; studies also showed hair regrowth 
in the sites of scalp biopsy when the dermal papilla had been 
removed. These are important findings with many practical thera-
peutic applications. . 
Our concepts of cell damage and repair were enlarged. The role 
of apoptosis was emphasized in the localization of disease in 
addition to the role of antibodies and cytokines .. There was 
significant progress in demonstrating autoantibodies in alopecia 
areata although the basic question remains whether these antibodies 
are intrinsic to the disease and its progression or whether they are 
epiphenomena. However, even as epiphenomena they could still 
play a role in the pathophysiology. Dr. Vandenbark, a keynote 
speaker, discussed some of the difficulties distinguishing viral 
antigens from autoimmune antigens. 
Dr. Skinner's demonstration of cytomegalic virus DNA in alo-
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pecia areata skin was extremely stimulating and raised the need for 
redefining Koch's postulates in the era of PCR. It also raises the 
question whether such putative etiologic or trigger factors are 
working with the susceptibility gene of the disease or with the 
severity gene of the immune response. 
There are significant needs in defining several aspects of basic 
hair biology including the hair cycle, and the control of potential 
molecules such as insulin growth factor 1 on hair growth. Mutant 
analysis of both the non-human and human mutants affecting hair 
structure should be extremely important as are studies of transgenic 
and knock-out mice. Dr. Chaplin, also a keynote speaker, made a 
strong case for defining all of the components of the lILA locus. He 
described 'a structural gene that does not have an obvious relationship 
to the innnune system yet is extremely important for the hair follicle 
and the skin. The complexity of pathophysiology was emphasized with 
the example of a simple genetic disease as may be induced in the K6 
transgenic mice. Analysis and control and basic knowledge of the 
innnune response will certainly help understand alopecia areata. 
SUMMARY 3S 
In addition to standardizing clinical criteria for clinical and 
molecular alopecia areata studies, it is strongly suggested that 
appropriate groups work with the Food and Drug Administration 
(FDA) to develop criteria for clinical trials in alopecia areata. In 
scleroderma, for example, criteria for clinical trials were developed 
by investigators in conjunction with the FDA. It is expected that 
systemic immune mediators will become available for trials and 
having such criteria will be extremely useful at that time. It was also 
suggested that investigators exchange sera whenever possible to 
enlarge the patient pool in genetic and immunologic studies and 
enhance the precision of interpreting the data. 
The National Alopecia Areata Foundation and National Institute 
of Arthritis and Musculoskeletal and Skin Diseases have been 
excellent catalysts for the development of research in alopecia 
areata. As we define better the basic biology of the hair follicle, the 
innnune response of the hair follicle, and genetic factors controlling 
the hair follicle, it is expected that these will lead to new preventive 
regimens as well as treatments for alopecia areata. 
A Molecular Approach to Alopecia Areata 
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U sing polymerase chain reaction (PCR) technique we have found evidence of cytomegalovirus (CMV) DNA in paraffin block sections of lesions of alopecia areata. Our interest in this association was first aroused 
by a 1s-year-old male patient who developed sore throat, arthral­
gias, fever, chills, and diffuse lymphadenopathy. Evaluation by 
several other physicians had failed to uncover an etiology. Tests for 
mononucleosis, among others, were negative. He developed wide­
spread alopecia areata with loss of most of the hair on his scalp and 
body. His symptoms suggested CMV infection; a convalescent 
serum IgG by EIA titer to CMV was 1.30 with positive being 
<0.25. Because of this one case we instituted further studies. 
Twenty-one of thirty-five alopecia areata patients had similarly 
elevated antibody titers. In situ hybridization tests on paraffin block 
biopsy specimens of 10 patients with alopecia areata were all 
negative. 
Specimens for PCR study were chosen from the archives of 
paraffin blocks at Baptist Memorial Hospital in Memphis, Tennes­
see. Specimen blocks were selected on the basis of characteristic 
morphology for alopecia areata, trichotillomania, or pattern hair 
loss. CMV antibody titer was not known for any of these specimens. 
DNA for PCR was obtained from paraffin-embedded sections by 
proteolytic digestion. CMV DNA sequences were amplified using 
two primer sets (directed against the CMV IE and LA regions) 
followed by hybridization with radiolabeled probes [1]. Appropri-
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ate positive and negative controls were included and consisted of 
DNA isolated from patients with CMV infection, plasmid DNA 
containing the IE gene region, samples lacking genomic DNA, and 
samples without primers. 
In addition, a primer set specific for human betaglobin (KM38-
GH20) was included to control for successful extraction of DNA 
from the paraffin. 
Twenty-one patient specimens were analyzed (10 alopecia 
areata; 11 from patients with other hair loss conditions [six 
androgenetic alopecia, five trichotillomania]). Of the alopecia 
areata samples, nine were positive for cytomegalovirus and one was 
negative; there were no DNA extraction failures. Of the other 
alopecias, all nine were negative for cytomegalovirus, with two 
DNA extraction failures. 
CMV, as a member of the herpes family of viruses, is thought to 
achieve latency following what is usually an inapparent clinical 
infection. The hair root is not an implausible site for such latency to 
occur. Murine cytomegalovirus has been found in dermal papillae 
of hair follicles following subcutaneous injection of virus into CD1 
mice [2]. Coincidentally, these mice also developed marked alope­
cia or sparse hair growth in the inoculation sites. 
Alopecia areata has been considered likely to be a manifestation 
of auto-immunity [3], although it has been suggested, also, that its 
ubiquitous lymphocytic infiltrate may be serving a useful role [4]. 
A lymphocytic surveillance of not-quite-Iatent CMV would 
explain much of the behavior of alopecia areata with its tendency to 
intermittent remissions and relapses. We consider this the likeliest 
explanation of alopecia areata. 
Support for this possibility comes from the report by Grimes [5] 
of PCR evidence of CMV in 12 of 13 cases of vitiligo, a closely 
related condition. 
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